Buy this Article for $10.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.


acute lymphoblastic leukemia (ALL), axicabtagene ciloleucel, CAR T-cell-related encephalopathy syndrome (CRES), CAR T cells, chemotherapy, chimeric antigen receptor, cytokine-release syndrome (CRS), neurologic toxicities, non-Hodgkin lymphoma, tisagenlecleucel



  1. Morrison, Felicia MSN, MBA, RN-BC


Abstract: With limited cancer treatment options available for patients with certain types of advanced or recurrent acute lymphoblastic leukemia and certain types of non-Hodgkin lymphoma, the recent FDA approvals of tisagenlecleucel (Kymriah, formerly known as CTL019), and axicabtagene ciloleucel (Yescarta), CAR T-cell therapy provides a new opportunity to achieve cancer remission for many patients.1,2 These genetically enhanced T cells can destroy cancer cells. This article explores the science behind CAR T-cell therapy and ways critical care nurses can recognize and intervene in potentially life-threatening adverse reactions associated with this new therapy: cytokine release syndrome and CAR T-cell-related encephalopathy syndrome.3